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Abstract
Despite receiving ‘weak no’ recommendations in the updated guidelines on treating patients with Idiopathic
Pulmonary Fibrosis (IPF), two key treatment options are pirfenidone and N-acetylcysteine (NAC), and both are used
in clinical practice. The efficacy of pirfenidone is supported by a number of Phase III trials as well as a Cochrane
meta-analysis. Tolerability data are also provided by clinical trials and a long-term extension phase of these studies.
Pirfenidone is approved in Europe for the treatment of patients with mild-to-moderate IPF. NAC-based therapy has
no such approval, but is commonly used to treat patients. A Phase III trial suggested some benefit of the NAC,
prednisone and azathioprine regimen for IPF patients, but the study had many limitations. A further study to
investigate this regimen, compared with a placebo alone arm, was recently stopped due to increased mortality in
the triple-therapy arm. Discussion of these data and recent findings highlight the importance of a further update
to the existing guidelines, so that IPF specialists can provide the most up-to-date advice and treatment to patients
in clinical practice.
Introduction
The 2011 guideline update on the treatment of Idiopathic
Pulmonary Fibrosis (IPF) unfortunately did not strongly
or weakly recommend any pharmacological agent for use.
[1] A strong recommendation was made against the use
of corticosteroids, colchicine, cyclosporine A, interferon g
1b, bosentan and etanercept. Treatments given ‘weak no’
recommendations were pirfenidone, anticoagulation,
N-acetylcysteine (NAC) monotherapy, and triple-therapy
with NAC, azathioprine and prednisone. For the latter
group, this has meant that they are not to be considered
suitable for use in the majority of patients but may be a
reasonable treatment choice for a minority of patients.
Pirfenidone received this recommendation despite data
from a Cochrane meta-analysis [2] supporting its efficacy,
although at the time the recommendations were finalised
results from two out of four trials [3-5] used in the
Cochrane meta-analysis were yet to be published. Of all
medications studied for the treatment of IPF, pirfenidone
currently has the highest grade of evidence to support its
efficacy and is the only medication approved for use in
this indication. Regardless of the 2011 recommendations,
triple-therapy with NAC, azathioprine and prednisone is
considered standard treatment by some treating physi-
cians in the field of IPF. This is mainly due to data com-
ing from the IFIGENIA study, [6] which despite its
numerous limitations suggested preservation of lung
function in patients with IPF. A further study [7] of this
triple-therapy regimen was underway, but recently the
triple-therapy arm of the study was stopped following a
planned interim analysis that revealed an increased rate
of death and hospitalisation compared with placebo. This
regimen is still used in practice, but this is off-label treat-
ment. The impact of data from these studies on the cur-
rent treatment paradigm will be discussed, along with
issues that remain to be addressed by the updated guide-
lines and the IPF community as a whole.
Data from key studies of NAC-based triple-
therapy
Data from the IFIGENIA Study provided support for the
use of NAC plus prednisone and azathioprine to treat
IPF patients. Patients were treated with high-dose NAC
(600 mg TID) plus prednisone and azathioprine. The pri-
mary endpoint of the study was change in vital capacity.
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The NAC-based triple-therapy was found to significantly
reduce decline in VC after one year of treatment. How-
ever, this study had several limitations. Not all patients
included in the study were included in the Intention-To-
Treat (ITT) analysis. Furthermore, as all patients were
treated with prednisone plus azathioprine, this did not
allow a direct comparison with patients treated only with
placebo, i.e. a placebo alone group. In view of the drop-
out rate from this study of approximately 30% (including
deaths) questions were raised regarding the clinical rele-
vance and robustness of the treatment effect. [8] Despite
these issues, the NAC, prednisone and azathioprine treat-
ment regimen is commonly used in clinical practice.
Subgroup analyses from the study confirmed the favour-
able effects of NAC on lung function, and patients with
less advanced disease at baseline appeared to be more
responsive to NAC treatment. [9]
The PANTHER-IPF Study was designed to determine
whether NAC-based triple-therapy could slow disease pro-
gression and improve lung function in patients with mod-
erate IPF. In addition, this study compared the triple-
therapy regimen with NAC monotherapy and placebo
alone. In 2011, the NIH announced that the triple-therapy
arm of the trial had been stopped due to increased mortal-
ity observed in this treatment group. [10] A recently
published statement by five European experts has
attempted to provide some urgently needed guidance on
the implications of these findings to routine clinical prac-
tice. [11] Meanwhile, the other two treatment arms have
continued, and some data from the terminated NAC, pre-
dnisone and azathioprine arm have just been published.
[7] Currently, if we have patients being treated with this
regimen we should discuss any concerns and decide the
next steps along with the patient in question.
Data from key studies of pirfenidone
Three Phase III studies have investigated the efficacy and
safety of pirfenidone in patients with IPF. The first was a
Japanese study in which patients were randomised to pir-
fenidone or placebo. [4] The primary endpoint was
change in vital capacity (VC) from baseline to 52 weeks.
Statistically significant differences were observed between
the pirfenidone and placebo groups for the primary end-
point along with secondary endpoints. Pirfenidone was
associated with a 44% reduction in the VC decline com-
pared with placebo (p=0.0416), and with a significant
increase in progression-free survival (p=0.0280). Pirfeni-
done was usually well tolerated. Data from this study led
to the approval of pirfenidone in Japan in 2008.
The multinational CAPACITY trials (CAPACTY 1 and
2) investigated the efficacy of pirfenidone in two large,
concurrent Phase III trials. Patients with mild-to-moderate
IPF were randomised to treatment with pirfenidone or
placebo. The primary endpoint of both studies was chan-
ged from baseline in percentage predicted FVC at week
72. Data from the CAPACITY 1 Study, and the pooled
analysis of both studies supported the efficacy of pirfeni-
done. The primary endpoint however was not met in
CAPACITY 2. Meta-analyses of data by Spagnolo et al. for
the Cochrane Collaboration [2] confirmed the treatment
effect of pirfenidone. Data from the two Japanese studies
[3,4] showed a statistically significant difference was
observed in terms of decline in VC in favour of pirfeni-
done. PFS data from the Phase III study by Taniguchi et
al. was combined with data from the CAPACITY Studies.
The overall result of this meta-analysis showed that pirfe-
nidone reduced the risk of disease progression by 30% in
patients with IPF. [2]
A recent review by Germany’s Federal Joint Committee
granted the additional benefit of pirfenidone in adults with
mild-to-moderate IPF, [12] despite an initial proposal
from the Institute for Quality and Efficiency in Health
Care (IQWiG) [13] that concluded ‘no proven benefit’.
The additional benefit was classified as Stage 4 (a non-
quantifiable benefit) in the rating system established under
German pharmaceutical law. This means that pirfenidone
is considered to have an additional benefit, which will
likely be defined in the future via experience in daily clini-
cal use or clinical studies.
In terms of safety, pirfenidone was usually well tolerated
at the standard 2403 mg/day dose in the CAPACITY Stu-
dies. There was no significant difference in the number of
patients experiencing serious treatment-emergent adverse
events between the pirfenidone and placebo groups (33%
and 31% respectively; pooled CAPACITY data). The most
common adverse events being gastrointestinal, skin disor-
ders and dizziness. These are consistent with the known
safety profile of pirfenidone and were generally mild-to-
moderate in severity. The extension phase of the CAPA-
CITY Studies (RECAP) aimed to assess the safety of
pirfenidone beyond the duration of these Phase III Studies.
At Week 72 of this extension phase, patients had been
treated with pirfenidone for a mean duration of 2.9 years,
with 114 patients treated at the full dose for at least three
years. Safety data from the RECAP extension phase con-
firm the tolerability of pirfenidone. [14] Common adverse
events observed were very similar to those observed in the
CAPACITY Studies, and were generally mild-to-moderate
in severity. Rash/photosensitivity occurred in fewer
patients from the RECAP Extension phase than in the
CAPACITY Studies (20% vs 44%). Interestingly, rash or
photosensitivity was more common among patients initiat-
ing treatment with pirfenidone compared with those who
were on continued treatment (28% vs 12%). [13] These
data provide further important information on treatment
with pirfenidone and demonstrate its tolerability.
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Conclusions
Based on the evidence available to date, pirfenidone is pro-
ven effective and generally well tolerated in the treatment
of patients with IPF. In addition, the tolerability of pirfeni-
done has been demonstrated in clinical trials and a long-
term extension phase. However, an inherent issue with
approval of pirfenidone in Europe is that it is indicated for
patients with mild-to-moderate disease. The approval in
these patients was based on the functional criteria used in
the CAPACITY studies, which were: FVC ≥50% of pre-
dicted value, DLCO ≥35% of predicted value, and a 6MWT
distance of ≥150 m. [4] In clinical practice it is therefore a
challenge to define patients with mild-to-moderate disease,
particularly in the absence of any current staging or classi-
fication system. It is essential that we determine the best
way to classify our patients with IPF so that we can give
them the most appropriate treatment based on their dis-
ease stage. The need for an update to the 2011 ATS/ERS/
JRS/ALAT recommendations document is highlighted by
the fact that four published studies [3-5] and a Cochrane
meta-analysis [2] support the patient benefit associated
with pirfenidone treatment, along with further safety data
from the long-term RECAP Study. [14] In addition, NAC-
based therapy is commonly used to treat IPF patients, and
we await the results from the PANTHER-IPF study
regarding the NAC monotherapy arm.
Authors’ contributions
All the authors contributed equally.
Competing interests
Dr Carlo Albera has served as investigator in clinical trials, consultant,
speaker, Steering Committee or Scientific Advisory Board member for:
Actelion, Almirall, Aptalis, Bayer, Centocor, Eli-Lilly, GSK, InterMune, Inc.
Acknowledgments
We acknowledge Dr Laura Carena for her support in managing the data. The
author thanks C. Trenam, I. Mandic and M. Smith of IntraMed Communications
for editorial assistance in the preparation of the manuscript. Development of
this article was supported by InterMune AG.
Declarations
This article has been published as part of Respiratory Research Volume 14
Supplement 1, 2013:IPF in 2011 – Key updates on guidelines and
therapeutics. The full contents of the supplement are available online at
http://respiratory-research.com/supplements/14/S1. Publication of this
supplement was supported by IntraMed Communications with funding from
InterMune, AG. InterMune is the manufacturer of pirfenidone, a product
mentioned in this article. The supplement originates from presentations
given at the “AIR Event: Advancing IPF Research. Working together to
translate IPF research into practice” held in Berlin in November 2011. The
publication was proposed by IntraMed Communications and developed in
consultation with the journal. All articles in the supplement have undergone
the journal’s standard peer review process.
Published: 16 April 2013
References
1. ATS/ERS/JRS/ALAT: An Official ATS/ERS/JRS/ALAT Statement: Idiopathic
Pulmonary Fibrosis: Evidence-Based Guidelines For Diagnosis and
Management. Am J Respir Crit Care Med 2011, 183:788-824.
2. Spagnolo P, Del Giovane C, Luppi F, et al: Non-steroid agents for
idiopathic pulmonary fibrosis (Review). Cochrane Database Syst Rev 2010,
9:CD003134.
3. Azuma A, Nukiwa T, Tsuboi E, et al: Double-blind, placebo-controlled trial
of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir
Crit Care Med 2005, 171:1040-7.
4. Taniguchi H, Ebina M, Kondoh Y, et al: Pirfenidone in idiopathic
pulmonary fibrosis. Eur Respir J 2010, 35:821-9.
5. Noble PW, Albera C, Bradford WZ, et al: Pirfenidone in patients with
idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet
2011, 377:1760-9.
6. Demedts M, Behr J, Buhl R, et al: High-dose acetylcysteine in idiopathic
pulmonary fibrosis. N Engl J Med 2005, 353:2229-42.
7. Idiopathic Pulmonary Fibrosis Clinical Research Network: Prednisone,
azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med
2012, 366(21):1968-77.
8. Hunninghake GW: Antioxidant therapy for idiopathic pulmonary fibrosis.
N Engl J Med 2005, 353:2285-87.
9. Behr J, Demedts M, Buhl R, et al: Lung function in idiopathic pulmonary
fibrosis–extended analyses of the IFIGENIA trial. Respir Res 2009, 10:101.
10. [http://www.nih.gov/news/health/oct2011/nhlbi-21.htm].
11. Wells AU, Behr J, Costabel U, et al: Triple therapy in idiopathic pulmonary





14. Costabel U, Albera C, Cohen A, et al: The long-term safety of pirfenidone
in patients with idiopathic pulmonary fibrosis (IPF): Interim data from
the RECAP extension study. Abstract 174 presented at the European
Respiratory Society Annual Congress, Amsterdam, The Netherlands, September
24-28, 2011 .
doi:10.1186/1465-9921-14-S1-S7
Cite this article as: Albera et al.: Where do we stand with IPF treatment?
Respiratory Research 2013 14(Suppl 1):S7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Albera et al. Respiratory Research 2013, 14(Suppl 1):S7
http://respiratory-research.com/content/14/S1/S7
Page 3 of 3
